| dc.contributor.author | Cheng, Richard Z | |
| dc.date.accessioned | 2020-04-21T03:03:22Z | |
| dc.date.available | 2020-04-21T03:03:22Z | |
| dc.date.issued | 2020-03-26 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S2590098620300154?via%3Dihub | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/1125 | |
| dc.description.abstract | Because the development of efficacious vaccines and antiviral drugstakes time, vitamin C and other antioxidants are among currently available agentsto mitigate COVID-19 associated ARDS. Given the fact that high-dose VC issafe, healthcare professionals should take a close look at this opportunity. Obviously, well-designed clinical studies are absolutely needed to developstandard protocols for bedside use. | en_US |
| dc.language | English | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Coronavirus | en_US |
| dc.subject | Ascorbic Acid | en_US |
| dc.title | Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Candidate therapeutics RD | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.relation.ispartofjournal | Medicine in Drug Discovery | en_US |
